Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APP | P05067 | 11/20 | 0.87 |
| ▸ | CYP2C9 | P11712 | 8/20 | 0.87 |
| ▸ | CYP2C19 | P33261 | 7/20 | 0.87 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.87 |
| ▸ | CYP3A4 | P08684 | 7/20 | 0.85 |
| ▸ | AKR1C3 | P42330 | 6/20 | 0.66 |
| ▸ | AKR1C2 | P52895 | 6/20 | 0.66 |
| ▸ | AKR1C1 | Q04828 | 3/20 | 0.66 |
| ▸ | AKR1B10 | O60218 | 1/20 | 0.66 |
| ▸ | AKR1C4 | P17516 | 1/20 | 0.66 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.62 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.62 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.62 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.62 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.62 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.62 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.51 |
| ▸ | LPAR1 | Q92633 | 1/20 | 0.42 |
| ▸ | LPAR3 | Q9UBY5 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2777333 | 0.92 | APP (1.00) | APPCYP2C9CYP2C19CYP2D6CYP3A4 | |
| SCHEMBL1371366 | 0.92 | APP (0.97) | APPCYP2C9CYP2C19CYP2D6CYP3A4 | |
| SCHEMBL2781848 | 0.90 | APP (0.84) | APPCYP2C9CYP2C19CYP2D6CYP3A4 | |
| SCHEMBL2776247 | 0.87 | APP (0.89) | APPCYP2C9CYP2C19CYP2D6CYP3A4 | |
| SCHEMBL1371930 | 0.83 | APP (0.82) | APPCYP2C9CYP2C19CYP2D6CYP3A4 | |
| SCHEMBL5448540 | 0.82 | APP (1.00) | APPCYP2C9CYP2C19CYP2D6CYP3A4 | |
| SCHEMBL411735 | 0.80 | APP (0.76) | APPCYP2C9CYP2C19CYP2D6CYP3A4 | |
| SCHEMBL1373506 | 0.77 | APP (1.00) | APPCYP2C9CYP2C19CYP2D6CYP3A4 | |
| SCHEMBL29926966 | 0.77 | APP (1.00) | APPCYP2C9CYP2C19CYP2D6CYP3A4 | |
| SCHEMBL1374530 | 0.77 | APP (0.85) | APPCYP2C9CYP2C19CYP2D6CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130165505-A1 | 1-PHENYLALKANECARBOXYLIC ACID DERIVATIVES FOR THE TREATMENT OF COGNITIVE IMPAIRMENT | CHIESI FARMACEUTICI S.P.A. (IT) | 2013-06-27 | — | — | US | claimed |
| US-7662995-B2 | 1-(2-Fluoro-4'-trifluoromethylbiphenyl-4-yl)cyclopropanecarboxylic acid, for example; treatment and/or prevention of Alzheimer's disease; inhibiting the release of A beta 42 peptide thereby being able to modulate gamma-secretase activity without affecting other important metabolic processes | CHIESI FARMACEUTICI S.P.A. (IT) | 2010-02-16 | — | — | US | claimed |
| US-9592210-B2 | 1-phenylalkanecarboxylic acid derivatives for the treatment of cognitive impairment | CHIESI FARMACEUTICI S.P.A. (IT) | 2017-03-14 | — | — | US | disclosed |
| US-20130165505-A1 | 1-PHENYLALKANECARBOXYLIC ACID DERIVATIVES FOR THE TREATMENT OF COGNITIVE IMPAIRMENT | CHIESI FARMACEUTICI S.P.A. (IT) | 2013-06-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130165505-A1 | 1-PHENYLALKANECARBOXYLIC ACID DERIVATIVES FOR THE TREATMENT OF COGNITIVE IMPAIRMENT | PSEN1, PSEN2, NAT1 | APP 15/4885CYP2C9 1978/4885CYP2C19 1159/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.